Selected research
Industry Research
Mecobalamin API Industry Research Report 2026
Market perspective
The global Mecobalamin API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mecobalamin API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mecobalamin API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mecobalamin API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mecobalamin API include Yufeng Industry Group, Yabao Pharmaceutical, Eisai, E-CSPC, Novartis, Ningxia Kingvit Pharmaceutical, Merck, HTBA and EUROAPI, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mecobalamin API market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mecobalamin API Market by Company
Yufeng Industry Group
Yabao Pharmaceutical
Eisai
E-CSPC
Novartis
Ningxia Kingvit Pharmaceutical
Merck
HTBA
EUROAPI
Atom Pharma
Mecobalamin API Segment by Type
Purity≥99%
Purity<99%
Mecobalamin API Segment by Application
Injectable Formulation
Sprays
Oral Formulation
Mecobalamin API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mecobalamin API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mecobalamin API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mecobalamin API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mecobalamin API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mecobalamin API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mecobalamin API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity≥99%
- Purity<99%
Applications
- Injectable Formulation
- Sprays
- Oral Formulation
Companies covered
- Yufeng Industry Group
- Yabao Pharmaceutical
- Eisai
- E-CSPC
- Novartis
- Ningxia Kingvit Pharmaceutical
- Merck
- HTBA
- EUROAPI
- Atom Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mecobalamin API Market Size (2021-2032)
- 2.2.2 Global Mecobalamin API Sales (2021-2032)
- 2.2.3 Global Mecobalamin API Market Average Price (2021-2032)
- 2.3 Mecobalamin API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Purity≥99%
- 2.3.3 Purity<99%
- 2.4 Mecobalamin API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Injectable Formulation
- 2.4.3 Sprays
- 2.4.4 Oral Formulation
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mecobalamin API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mecobalamin API Sales (kg) of Manufacturers (2021-2026)
- 3.3 Global Mecobalamin API Revenue of Manufacturers (2021-2026)
- 3.4 Global Mecobalamin API Average Price by Manufacturers (2021-2026)
- 3.5 Global Mecobalamin API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mecobalamin API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mecobalamin API, Product Type & Application
- 3.8 Global Manufacturers of Mecobalamin API, Established Date
- 3.9 Global Mecobalamin API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yufeng Industry Group
- 4.1.1 Yufeng Industry Group Company Information
- 4.1.2 Yufeng Industry Group Business Overview
- 4.1.3 Yufeng Industry Group Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yufeng Industry Group Mecobalamin API Product Portfolio
- 4.1.5 Yufeng Industry Group Recent Developments
- 4.2 Yabao Pharmaceutical
- 4.2.1 Yabao Pharmaceutical Company Information
- 4.2.2 Yabao Pharmaceutical Business Overview
- 4.2.3 Yabao Pharmaceutical Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Yabao Pharmaceutical Mecobalamin API Product Portfolio
- 4.2.5 Yabao Pharmaceutical Recent Developments
- 4.3 Eisai
- 4.3.1 Eisai Company Information
- 4.3.2 Eisai Business Overview
- 4.3.3 Eisai Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eisai Mecobalamin API Product Portfolio
- 4.3.5 Eisai Recent Developments
- 4.4 E-CSPC
- 4.4.1 E-CSPC Company Information
- 4.4.2 E-CSPC Business Overview
- 4.4.3 E-CSPC Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 E-CSPC Mecobalamin API Product Portfolio
- 4.4.5 E-CSPC Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Mecobalamin API Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Ningxia Kingvit Pharmaceutical
- 4.6.1 Ningxia Kingvit Pharmaceutical Company Information
- 4.6.2 Ningxia Kingvit Pharmaceutical Business Overview
- 4.6.3 Ningxia Kingvit Pharmaceutical Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ningxia Kingvit Pharmaceutical Mecobalamin API Product Portfolio
- 4.6.5 Ningxia Kingvit Pharmaceutical Recent Developments
- 4.7 Merck
- 4.7.1 Merck Company Information
- 4.7.2 Merck Business Overview
- 4.7.3 Merck Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Merck Mecobalamin API Product Portfolio
- 4.7.5 Merck Recent Developments
- 4.8 HTBA
- 4.8.1 HTBA Company Information
- 4.8.2 HTBA Business Overview
- 4.8.3 HTBA Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 HTBA Mecobalamin API Product Portfolio
- 4.8.5 HTBA Recent Developments
- 4.9 EUROAPI
- 4.9.1 EUROAPI Company Information
- 4.9.2 EUROAPI Business Overview
- 4.9.3 EUROAPI Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 EUROAPI Mecobalamin API Product Portfolio
- 4.9.5 EUROAPI Recent Developments
- 4.10 Atom Pharma
- 4.10.1 Atom Pharma Company Information
- 4.10.2 Atom Pharma Business Overview
- 4.10.3 Atom Pharma Mecobalamin API Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Atom Pharma Mecobalamin API Product Portfolio
- 4.10.5 Atom Pharma Recent Developments
5 Global Mecobalamin API Market Scenario by Region
- 5.1 Global Mecobalamin API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mecobalamin API Sales by Region: 2021-2032
- 5.2.1 Global Mecobalamin API Sales by Region: 2021-2026
- 5.2.2 Global Mecobalamin API Sales by Region: 2027-2032
- 5.3 Global Mecobalamin API Revenue by Region: 2021-2032
- 5.3.1 Global Mecobalamin API Revenue by Region: 2021-2026
- 5.3.2 Global Mecobalamin API Revenue by Region: 2027-2032
- 5.4 North America Mecobalamin API Market Facts & Figures by Country
- 5.4.1 North America Mecobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mecobalamin API Sales by Country (2021-2032)
- 5.4.3 North America Mecobalamin API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Mecobalamin API Market Facts & Figures by Country
- 5.5.1 Europe Mecobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mecobalamin API Sales by Country (2021-2032)
- 5.5.3 Europe Mecobalamin API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Mecobalamin API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mecobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mecobalamin API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mecobalamin API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mecobalamin API Market Facts & Figures by Country
- 5.7.1 South America Mecobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mecobalamin API Sales by Country (2021-2032)
- 5.7.3 South America Mecobalamin API Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Mecobalamin API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mecobalamin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mecobalamin API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mecobalamin API Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Mecobalamin API Sales by Type (2021-2032)
- 6.1.1 Global Mecobalamin API Sales by Type (2021-2032) & (kg)
- 6.1.2 Global Mecobalamin API Sales Market Share by Type (2021-2032)
- 6.2 Global Mecobalamin API Revenue by Type (2021-2032)
- 6.2.1 Global Mecobalamin API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Mecobalamin API Revenue Market Share by Type (2021-2032)
- 6.3 Global Mecobalamin API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Mecobalamin API Sales by Application (2021-2032)
- 7.1.1 Global Mecobalamin API Sales by Application (2021-2032) & (kg)
- 7.1.2 Global Mecobalamin API Sales Market Share by Application (2021-2032)
- 7.2 Global Mecobalamin API Revenue by Application (2021-2032)
- 7.2.1 Global Mecobalamin API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mecobalamin API Revenue Market Share by Application (2021-2032)
- 7.3 Global Mecobalamin API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mecobalamin API Value Chain Analysis
- 8.1.1 Mecobalamin API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mecobalamin API Production Mode & Process
- 8.2 Mecobalamin API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mecobalamin API Distributors
- 8.2.3 Mecobalamin API Customers
9 Global Mecobalamin API Analyzing Market Dynamics
- 9.1 Mecobalamin API Industry Trends
- 9.2 Mecobalamin API Industry Drivers
- 9.3 Mecobalamin API Industry Opportunities and Challenges
- 9.4 Mecobalamin API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst